Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | TYK2 | P29597 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.60 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960964 | 0.85 | NPC1 (0.74) | LMNARAB9ANPC1POLBL3MBTL1 | |
| SCHEMBL3794850 | 0.85 | NPC1 (0.74) | LMNARAB9ANPC1POLBL3MBTL1 | |
| SCHEMBL11921357 | 0.84 | GAA (1.00) | GAATYK2RAB9ANPC1POLB | |
| SCHEMBL23458450 | 0.83 | GSK3A (0.60) | GAATYK2LMNARAB9APOLB | |
| SCHEMBL31171396 | 0.82 | HDAC3 (0.68) | LMNARAB9ANPC1L3MBTL1ALDH1A1 | |
| SCHEMBL1704449 | 0.81 | NPC1 (0.69) | GAALMNARAB9ANPC1KMT2A | |
| SCHEMBL16583878 | 0.81 | NPC1 (0.73) | LMNARAB9ANPC1L3MBTL1TP53 | |
| SCHEMBL18086516 | 0.81 | RAB9A (0.68) | GAATYK2LMNARAB9ANPC1 | |
| SCHEMBL28577755 | 0.81 | NPC1 (0.73) | LMNARAB9ANPC1L3MBTL1TP53 | |
| SCHEMBL1520680 | 0.80 | RAB9A (0.77) | GAATYK2LMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
| WO-2010139966-A1 | AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2010-12-09 | — | — | WO | disclosed |
| CN-101010323-B | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD | 2010-06-16 | — | — | CN | disclosed |
| CN-101010323-A | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-01 | — | — | CN | disclosed |
| CN-1930170-A | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-03-14 | — | — | CN | disclosed |
| CN-1890240-A | Diazabicyclononene derivatives and their use as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-01-03 | — | — | CN | disclosed |
| CN-1890239-A | Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain | ACTELION PHARMACEUTICALS LTD (CH) | 2007-01-03 | — | — | CN | disclosed |
| CN-1867568-A | Diazabicyclononene derivatives and their use as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-22 | — | — | CN | disclosed |
| CN-1863773-A | Tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | GAA 2774/4885TYK2 2832/4885LMNA 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.